Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 2, 2020
Daily News
November 2, 2020
- Shionogi Drops March-End Goal to Start Clinical Trials for COVID-19 Treatment
November 2, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Clear PAFSC Review
November 2, 2020
- Shionogi Sales Sag 9.3% in April-September on COVID-19, Price Cuts
November 2, 2020
- Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending
November 2, 2020
- Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
November 2, 2020
- MHLW to Introduce Vaccination Facilitation System for Wholesalers, Medical Institutions
November 2, 2020
- European Regulators Accept Aducanumab for Review: Biogen/Eisai
November 2, 2020
- Ex-Merck Serono President Leo Lee Becomes Japan Chief of Novartis
November 2, 2020
- Lilly Pairs Up with Daiichi Sankyo to Commercialize Migraine Med Galcanezumab in Japan
November 2, 2020
- Daiichi Sankyo to Buyback 60 Million of Own Shares, Canceling 180 Million Treasury Shares
November 2, 2020
- Astellas Completes US iota Buyout to Shore Up Development of Implantable Medical Devices
November 2, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…